Dr. Reddy's Laboratories (RDY) Competitors $13.25 +0.03 (+0.23%) As of 04/14/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDY vs. ARGX, ONC, BNTX, TEVA, ITCI, SMMT, GMAB, MRNA, VTRS, and QGENShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. argenx Beigene BioNTech Teva Pharmaceutical Industries Intra-Cellular Therapies Summit Therapeutics Genmab A/S Moderna Viatris Qiagen Dr. Reddy's Laboratories (NYSE:RDY) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership. Which has more risk and volatility, RDY or ARGX? Dr. Reddy's Laboratories has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Does the MarketBeat Community favor RDY or ARGX? argenx received 335 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 67.35% of users gave argenx an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% argenxOutperform Votes65667.35% Underperform Votes31832.65% Which has stronger earnings and valuation, RDY or ARGX? Dr. Reddy's Laboratories has higher revenue and earnings than argenx. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$311.31B0.04$668M$0.6321.03argenx$2.19B16.82-$295.05M$12.5948.16 Do analysts prefer RDY or ARGX? Dr. Reddy's Laboratories presently has a consensus target price of $17.00, indicating a potential upside of 28.30%. argenx has a consensus target price of $690.33, indicating a potential upside of 13.84%. Given Dr. Reddy's Laboratories' higher possible upside, equities research analysts plainly believe Dr. Reddy's Laboratories is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50argenx 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.91 Does the media refer more to RDY or ARGX? In the previous week, argenx had 25 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 38 mentions for argenx and 13 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.13 beat argenx's score of 0.93 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive argenx 19 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is RDY or ARGX more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to argenx's net margin of -2.11%. Dr. Reddy's Laboratories' return on equity of 17.87% beat argenx's return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% argenx -2.11%-1.45%-1.29% Do insiders and institutionals have more ownership in RDY or ARGX? 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Summaryargenx beats Dr. Reddy's Laboratories on 11 of the 19 factors compared between the two stocks. Remove Ads Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$11.06B$6.35B$5.35B$18.52BDividend Yield0.65%3.23%5.11%4.25%P/E Ratio21.106.7721.6531.06Price / Sales0.04228.59376.3226.47Price / Cash13.2565.6738.1517.54Price / Book2.945.886.444.29Net Income$668M$141.32M$3.20B$1.02B7 Day Performance5.28%5.18%6.67%4.23%1 Month Performance4.38%-12.93%-6.27%-6.79%1 Year Performance-7.24%-14.85%8.56%-0.03% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories3.0786 of 5 stars$13.25+0.2%$17.00+28.3%-7.2%$11.06B$311.31B21.1024,800Positive NewsARGXargenx3.1269 of 5 stars$550.00-0.9%$687.00+24.9%+60.4%$33.42B$2.19B-625.00650High Trading VolumeONCBeigene2.2846 of 5 stars$220.54-7.5%$310.40+40.7%N/A$21.76B$3.81B-26.7610,600Gap DownBNTXBioNTech2.5187 of 5 stars$86.82-1.4%$143.44+65.2%+18.3%$20.83B$2.75B-41.343,080Gap DownTEVATeva Pharmaceutical Industries3.0106 of 5 stars$13.91+0.8%$23.43+68.5%+2.1%$15.77B$16.54B-9.5936,800Analyst DowngradeOptions VolumePositive NewsITCIIntra-Cellular Therapies3.4982 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.6255 of 5 stars$17.32-0.2%$35.40+104.4%+613.0%$12.78B$700,000.00-61.85110Gap UpGMABGenmab A/S4.2212 of 5 stars$18.19-1.1%$41.33+127.2%-34.0%$12.04B$21.53B10.451,660Short Interest ↓Gap DownMRNAModerna4.3313 of 5 stars$25.64+2.1%$59.00+130.1%-74.5%$9.91B$3.20B-2.763,900Positive NewsGap UpVTRSViatris2.9578 of 5 stars$7.61-0.1%$10.50+38.0%-32.7%$9.08B$14.74B-10.2837,000High Trading VolumeQGENQiagen3.4869 of 5 stars$40.33+5.4%$47.71+18.3%+8.3%$8.96B$1.98B112.296,030High Trading Volume Remove Ads Related Companies and Tools Related Companies argenx Alternatives Beigene Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Intra-Cellular Therapies Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RDY) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
